Company intelligence / Profile preview

Zhifeilong

Chongqing, Chongqing, China

Ownership: Private
Employees: ~4500
Development stage: Other

Overview

Zhifei has several commercial vaccines (e.g., COVID-19, TB, Hib, meningococcus), with strong revenue and broad clinical activity; newest programs include quadrivalent influenza vaccine entering clinical and production registration phases

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccineBiologicRecombinant proteinPolysaccharide conjugateSmall molecule
Industry: Pharma

Partnerships

MSD (Merck Sharp & Dohme – distribution of Gardasil, Gardasil 9, Rotateq, Pneumovax 23, Vaqta, etc.)

Beyond the preview

Go deeper on Zhifeilong.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhifeilong.

Explore the full profile